It is a GLP-1 agonist like the other medications in this chapter, and also a glucose-dependent insulinotropic polypeptide (GIP) agonist
Most individuals still enjoy meals but feel more in control
Building upon these imaging advances, GLP-1R-targeted NPs have been developed for therapeutic applications
Ghusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, Hurtado MD, Acosta A: Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity
Our medications belong to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists
Definitive AD answers: Await Phase 3 semaglutide results